Inflammation and Fibrosis in Sleep-Disordered Breathing after Acute Myocardial Infarction.

acute myocardial infarction inflammation myocardial fibrosis procollagen III type aminoterminal propeptide sleep-disordered breathing

Journal

Biomedicines
ISSN: 2227-9059
Titre abrégé: Biomedicines
Pays: Switzerland
ID NLM: 101691304

Informations de publication

Date de publication:
11 Jan 2024
Historique:
received: 30 11 2023
revised: 13 12 2023
accepted: 08 01 2024
medline: 23 1 2024
pubmed: 23 1 2024
entrez: 23 1 2024
Statut: epublish

Résumé

After acute myocardial infarction (AMI), inflammatory processes promote tissue remodeling at the infarct site. Procollagen III amino-terminal propeptide (PIIINP) is a circulating biomarker of type III collagen synthesis that has been shown to be associated with changes in left ventricular ejection fraction (LVEF) and predicts the occurrence of heart failure after AMI. We hypothesize that sleep-disordered breathing (SDB) promotes inflammation and myocardial fibrosis, leading to reduced myocardial salvage. Therefore, in patients with first-time AMI successfully treated with percutaneous coronary intervention (PCI), we aimed to investigate whether circulating levels of high-sensitivity C-reactive protein (hs-CRP) and PIIINP are elevated in patients with SDB compared to patients without SDB. This cross-sectional analysis included a total of 88 eligible patients with first AMI and PCI pooled from two prospective studies and stratified according to the apnea-hypopnea index (AHI, with SDB: AHI ≥ 15 h The presence of obstructive SDB after AMI was independently associated with increased circulating levels of hs-CRP and PIIINP. Our results emphasize the important role of SDB as a common comorbidity and indicate increased inflammation and myocardial fibrosis in these patients.

Sections du résumé

BACKGROUND BACKGROUND
After acute myocardial infarction (AMI), inflammatory processes promote tissue remodeling at the infarct site. Procollagen III amino-terminal propeptide (PIIINP) is a circulating biomarker of type III collagen synthesis that has been shown to be associated with changes in left ventricular ejection fraction (LVEF) and predicts the occurrence of heart failure after AMI. We hypothesize that sleep-disordered breathing (SDB) promotes inflammation and myocardial fibrosis, leading to reduced myocardial salvage. Therefore, in patients with first-time AMI successfully treated with percutaneous coronary intervention (PCI), we aimed to investigate whether circulating levels of high-sensitivity C-reactive protein (hs-CRP) and PIIINP are elevated in patients with SDB compared to patients without SDB.
METHODS AND RESULTS RESULTS
This cross-sectional analysis included a total of 88 eligible patients with first AMI and PCI pooled from two prospective studies and stratified according to the apnea-hypopnea index (AHI, with SDB: AHI ≥ 15 h
CONCLUSIONS CONCLUSIONS
The presence of obstructive SDB after AMI was independently associated with increased circulating levels of hs-CRP and PIIINP. Our results emphasize the important role of SDB as a common comorbidity and indicate increased inflammation and myocardial fibrosis in these patients.

Identifiants

pubmed: 38255259
pii: biomedicines12010154
doi: 10.3390/biomedicines12010154
pii:
doi:

Types de publication

Journal Article

Langues

eng

Subventions

Organisme : ResMed Foundation
ID : 000000
Organisme : ResMed (Germany)
ID : 000000
Organisme : Philips Home Healthcare Solutions
ID : 000000
Organisme : Faculty of Medicine of the University of Regensburg
ID : 000000

Auteurs

Jan Pec (J)

Department of Internal Medicine II, University Hospital Regensburg, 93053 Regensburg, Germany.

Stefan Buchner (S)

Department of Internal Medicine, Cham Hospital, 93413 Cham, Germany.

Henrik Fox (H)

Clinic for General and Interventional Cardiology/Angiology, Heart and Diabetes Center NRW, Ruhr University Bochum, 32545 Bad Oeynhausen, Germany.

Olaf Oldenburg (O)

Center for Cardiology, Ludgerus-Kliniken, 48153 Münster, Germany.

Stefan Stadler (S)

Department of Internal Medicine II, University Hospital Regensburg, 93053 Regensburg, Germany.

Lars S Maier (LS)

Department of Internal Medicine II, University Hospital Regensburg, 93053 Regensburg, Germany.

Michael Arzt (M)

Department of Internal Medicine II, University Hospital Regensburg, 93053 Regensburg, Germany.

Stefan Wagner (S)

Department of Internal Medicine II, University Hospital Regensburg, 93053 Regensburg, Germany.

Classifications MeSH